Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Non-Current Debt (2016 - 2025)

Cumberland Pharmaceuticals' Non-Current Debt history spans 15 years, with the latest figure at $5.2 million for Q4 2025.

  • For Q4 2025, Non-Current Debt fell 48.5% year-over-year to $5.2 million; the TTM value through Dec 2025 reached $5.2 million, down 48.5%, while the annual FY2025 figure was $5.2 million, 48.5% down from the prior year.
  • Non-Current Debt for Q4 2025 was $5.2 million at Cumberland Pharmaceuticals, roughly flat from $5.2 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $20.0 million in Q1 2022 and bottomed at $5.2 million in Q1 2025.
  • The 5-year median for Non-Current Debt is $15.0 million (2021), against an average of $13.0 million.
  • The largest annual shift saw Non-Current Debt soared 35.71% in 2022 before it crashed 67.43% in 2025.
  • A 5-year view of Non-Current Debt shows it stood at $15.0 million in 2021, then grew by 8.0% to $16.2 million in 2022, then decreased by 20.23% to $12.9 million in 2023, then dropped by 21.26% to $10.2 million in 2024, then tumbled by 48.5% to $5.2 million in 2025.
  • Per Business Quant, the three most recent readings for CPIX's Non-Current Debt are $5.2 million (Q4 2025), $5.2 million (Q3 2025), and $5.2 million (Q2 2025).